Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Research Report - Size, Share, Growth, and Trend Analysis | Forecast (2025 - 2030)
Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market Size (2025-2030)
The Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market represents a rapidly evolving segment of oncology therapeutics, addressing a subtype of NSCLC characterized by EGFR gene mutations. These mutations drive tumor growth, making targeted therapies a cornerstone of treatment. The market encompasses innovative therapies across first, second, and third-generation EGFR inhibitors, combination treatments, and mutation-specific therapies, revolutionizing patient outcomes in both treatment-naïve and resistant cases.
Disruptive Impact and Opportunities:
EGFR-NSCLC therapies have disrupted traditional treatment paradigms, providing precision medicine approaches that enhance efficacy while minimizing systemic side effects. New therapies addressing resistance mutations like T790M and C797S drive market growth. Easy administration methods, particularly oral therapies, improve patient compliance. Safe treatment options reduce toxicity profiles compared to chemotherapy. Big revenue potential as therapies expand into earlier treatment lines and combination regimens.
Emerging Drugs:
- Nazartinib
- Capmatinib
- JNJ-61186372 (JNJ-6372)
- Lazertinib
Marketed Drugs:
- Tagrisso (Osimertinib)
- Vizimpro (Dacomitinib)
- Tarceva (Erlotinib)
- Iressa (Gefitinib)
- Gilotrif (Afatinib)
Key Companies:
- AstraZeneca
- Pfizer
- Astellas Pharma
- Genentech
- Boehringer Ingelheim Pharmaceuticals
- Novartis
- Janssen Research & Development
- Takeda
Market Segmentation:
By Type
- First-Generation EGFR Inhibitors
- Gefitinib
- Erlotinib
- Second-Generation EGFR Inhibitors
- Afatinib
- Dacomitinib
- Third-Generation EGFR Inhibitors
- Osimertinib
- Combination Therapies
- EGFR Inhibitors with Chemotherapy
- EGFR Inhibitors with Immunotherapy
- Mutation-Specific Therapies
- T790M Mutation-Targeted Therapies
- Exon 19 Deletion and L858R Mutation Therapies
- Resistance Management Therapies
- C797S Mutation Therapies
- Supportive Care Treatments
- Symptom Management Drugs
By Administration Type
- Oral Administration
- Tablets
- Capsules
- Intravenous Administration
- Injection-Based Therapies
- Infusion-Based Therapies
What’s in It for You?
- Understand emerging drug landscapes and resistance management solutions.
- Identify lucrative investment opportunities in mutation-specific and combination therapies.
- Gain insights into competitive strategies of key market players.
- Leverage patient-centric trends to align R&D and commercialization strategies effectively.
- Epidermal Growth Factor Receptor-Non Small Cell Lung Cancer (EGFR-NSCLC) Market - Executive Summary
- Introduction
- Objectives
- Key Findings
- Market Size 2025 & 2030: By Key Country (10MM)
- Global Market Size 2025 & 2030: By Key Segment
- Key Investments & Startup Analysis
- Research Methodology
- Understanding the Disease
- Disease Overview
- Classification
- Signs and Symptoms
- Risk Factors
- Causes
- Disease Biology & Digital Innovations
- Stages & Staging System
- Diagnostic Algorithm
- Current Treatment Practices & Algorithm
- Current Standard of Care and Treatment Gaps
- Patient Demographics and Treatment Pathways
- Guidelines
- Unmet Needs
- Epidemiology and Patient Population
- Epidemiology Key Findings
- Assumptions and Rationale: 10MM
- Epidemiology Scenario: 10MM
- U.S. Epidemiology Scenario
- EU-5 Epidemiology
- U.K. Epidemiology Scenario
- Germany Epidemiology Scenario
- France Epidemiology Scenario
- Italy Epidemiology Scenario
- Spain Epidemiology Scenario
- Japan Epidemiology Scenario
- China Epidemiology Scenario
- Australia Epidemiology Scenario
- India Epidemiology Scenario
- Real-world Data & Real-world Evidence
- Drug Development Landscape
- Existing Key Drug Candidate Profiles/ Marketed Therapies
- Competitive Analysis and Differentiation
- Overview of Similar/Competing Drugs in Clinical Trials
- Future Trends and Emerging Drugs
- Regulatory Strategy and Potential Challenges
- Regulatory Pathways in Key Markets
- Anticipated Regulatory Hurdles and Mitigation Strategies
- Case Studies in Oncology Drug Regulation
- Impact of Potential Changes to Regulatory Framework
- Commercial Landscape
- Market Size & Growth Rates
- Key Approvals & Anticipated Loss of Exclusivity
- PESTLE & Porter’s Five Forces Analysis
- Market Shares, Positioning/Ranking
- Market Drivers
- Identification of Threats
- Digital Evolution in Commercialization
- Market Segmentation
- Pricing, Reimbursement, and Access
- Competitive Pricing Analysis
- Reimbursement Landscape and Challenges
- Strategies for Market Access and Equity
- Patient Spending/Expenditure Analysis
- Future Trends, Disruptions, and Opportunities
- Analysis of Emerging Trends
- Technological Impact
- Impact of Potential Market Disruptors
- Opportunities for Future Development and Expansion
- Considerations for Investment Opportunities
- Global Market Dynamics
- Regional Regulatory Disparities
- Cross-Border Partnership Strategies
- Global Supply Chain Dynamics
- Case Studies: Success and Failure in Global Markets
- Strategies for Global Expansion and Localization
- Company Profiles
Download Sample
Choose License Type
2500
4250
5250
6900
